Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04250051
Title Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University

acute myeloid leukemia


Cytarabine + Filgrastim + Fludarabine + Ivosidenib


Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST